Lupin Limited · NSE:LUPIN
Lupin — Q3 FY2020 Earnings Presentation
14 slides from Lupin's earnings presentation, Feb 7, 2020
Slide 1: Exchange covering letter for Q3 FY2020 Investor Presentation
Od February 7, 2020 LU P l ei The BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (East), Mumbai - 400 051. Dear Sirs, Sub:Q3 FY2020 Investor Presentation. Pursuant to
Slide 2: Investor Presentation Q3 FY2020
Investor Presentation Q3 FY2020 Feb 07, 2020
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • McKesson Supplier of the Year Award - 2019 • Walmart Supplier of the Year Award - 2018 • Cardinal Supply Chain Excellence Award – 2018 • India Pharma Innovation of the Year 2019 - Department of Pharmaceuticals, Govt. of India • Operational Excellence in Manufacturing –
Slide 5: Q3 FY2020 Snapshot
Q3 FY2020 Snapshot Sales1 (INR mn, YoY Growth) Important developments Commercial India, North America, Mr. Nilesh.D.Gupta 12,969, 9% Managing Director • India branded formulations (up 11.9% YoY in 13,766, (3%) Lupin Limited 9MFY20) continued to outpace IPM growth • Divested Japan Generics businesses
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Business Strong Complex Specialty Foundation Generics Focus Focus Amongst the Top 10 Investing heavily in Committed to building generic companies in developing high barrier a strong specialty the World products business Sustain and Grow Portfolio Execution Bu
Slide 7: Q3 FY2020 Financial Results Review
Q3 FY2020 Financial Results Review
Slide 8: P&L Highlights – Q3 FY2020
P&L Highlights – Q3 FY2020 % of % of QoQ % of YoY Amount in INR mn Q3 FY20 Q2 FY20 Q3 FY19 sales sales growth sales growth Net sales 37,161 100.0% 38,202 100.0% (2.7%) 38,212 100.0% (2.8%) Other operating income 532 620 1,262 Total revenue 37,693 38,822 (2.9%) 39,474 (4.5%) Gross profit 23,568 63.4%
Slide 9: Exceptional Items – Q3 FY2020
Exceptional Items – Q3 FY2020 Kyowa Divestiture Gavis Impairment • Divested entire stake (99.82%) in our erstwhile Japanese • Changes in the pipeline value of Gavis portfolio, resulted in subsidiary, Kyowa Pharmaceutical to Unison Capital. The deal reassessment of the fair value of Gavis and excepti
Slide 10: North America
Q3FY20 North America 37% 35% YoY 2.9% QoQ 3.9% Stabilized base business Consolidating our position in the US1 31% average market share1 US portfolio progressing • Maximize uptake for Levothyroxine, post planned capacity expansion 4 175 152 • Base business stabilized • SolosecTM: Initial response to
Slide 11: India
Q3FY20 India 35% 35% YoY 9.0% QoQ 3.4% India business continues to be robust Leadership across cardiac, diabetes, and respiratory India quarterly Sales (INR bn) 3 Year CAGR% Lupin Rank1 13.1 13.4 13.0 MAT MAT 11.9 Therapy Market Lupin 10.5 Dec-16 Dec-19 Acute 8% 6% 12 13 Chronic 11% 15% 5 4 Cardiac
Slide 12: Other Markets
Other Markets • Germany: EUR 9.5 mn sales in Q3 FY20 (up 38% YoY) EU5 • ARV’s, Women´s Health and CNS are the key focus therapeutic segments Developed • NaMusclaTM - Broadening direct presence and partnering with country specific distribution partners • 4th largest generics player1 Australia • Biosi
Slide 13: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence OPERATIONS 100 24 8 Countries where Countries with Countries with RESEARCH products are sold marketing offices subsidiaries 15 7 Manufacturing Sites R&D Sites ◼ 12 USFDA inspected sites ◼ 424 US ANDAs; 272 approved ◼ 30 bn+ ex
Slide 14: Thank You
L LUPIN THANK YOU